Elevated serum levels of M30 and M65 in patients with locally advanced head and neck tumors

Ozturk B., Coskun U., Sancak B., Yaman E., Buyukberber S., Benekli M.

INTERNATIONAL IMMUNOPHARMACOLOGY, cilt.9, sa.5, ss.645-648, 2009 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 9 Sayı: 5
  • Basım Tarihi: 2009
  • Doi Numarası: 10.1016/j.intimp.2009.02.004
  • Dergi Adı: INTERNATIONAL IMMUNOPHARMACOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.645-648
  • Anahtar Kelimeler: Head and neck tumor, Apoptosis, M30, M65, CASPASE-CLEAVED CYTOKERATIN-18, APOPTOSIS PROTEIN XIAP, X-LINKED INHIBITOR, CELL-DEATH, CIRCULATING BIOMARKERS, CLINICAL-EFFICACY, CANCER, REORGANIZATION, QUALIFICATION, VALIDATION
  • Gazi Üniversitesi Adresli: Evet

Özet

Background: M30-Apoptosense and M65 ELISAs can detect caspase cleaved and intact forms of cytokeratin 18. As biologic marker of cell death, both assays can be useful to evaluate prognosis and chemotherapy response in the patients with breast, lung, and endometrium cancer. In the present study, we measured serum M30 and M65 levels in the patients with locally advanced head and neck tumors, and compared with healthy controls.